Allworth Financial LP Has $1.87 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Allworth Financial LP lifted its holdings in Bristol-Myers Squibb (NYSE:BMYGet Rating) by 15.6% in the 2nd quarter, Holdings Channel.com reports. The firm owned 24,295 shares of the biopharmaceutical company’s stock after buying an additional 3,280 shares during the quarter. Allworth Financial LP’s holdings in Bristol-Myers Squibb were worth $1,871,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of BMY. Mizuho Securities Co. Ltd. boosted its position in Bristol-Myers Squibb by 239.0% during the 1st quarter. Mizuho Securities Co. Ltd. now owns 339 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 239 shares during the last quarter. Spectrum Management Group LLC boosted its position in Bristol-Myers Squibb by 113.1% during the 1st quarter. Spectrum Management Group LLC now owns 341 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 181 shares during the last quarter. Nauset Wealth Management. LLC acquired a new position in Bristol-Myers Squibb during the 1st quarter worth approximately $27,000. Conrad Siegel Investment Advisors Inc. acquired a new position in Bristol-Myers Squibb during the 1st quarter worth approximately $28,000. Finally, Evolution Advisers Inc. acquired a new position in Bristol-Myers Squibb during the 1st quarter worth approximately $29,000. Institutional investors and hedge funds own 76.54% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of recent research reports. BMO Capital Markets upped their price target on Bristol-Myers Squibb from $92.00 to $94.00 and gave the stock an “outperform” rating in a research report on Monday, September 12th. Citigroup reiterated a “buy” rating and set a $90.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday, June 3rd. Berenberg Bank cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $82.00 to $76.00 in a research note on Wednesday, September 14th. Bank of America upped their price objective on Bristol-Myers Squibb from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, June 6th. Finally, UBS Group upped their price objective on Bristol-Myers Squibb to $73.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 27th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $76.36.

Insider Buying and Selling at Bristol-Myers Squibb

In other news, CEO Giovanni Caforio sold 50,000 shares of the stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $71.84, for a total transaction of $3,592,000.00. Following the sale, the chief executive officer now directly owns 501,104 shares of the company’s stock, valued at approximately $35,999,311.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO Giovanni Caforio sold 50,000 shares of the stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $71.84, for a total transaction of $3,592,000.00. Following the sale, the chief executive officer now directly owns 501,104 shares of the company’s stock, valued at approximately $35,999,311.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO David V. Elkins sold 133,951 shares of the stock in a transaction on Tuesday, September 13th. The stock was sold at an average price of $71.30, for a total value of $9,550,706.30. Following the sale, the chief financial officer now directly owns 100,460 shares in the company, valued at $7,162,798. The disclosure for this sale can be found here. Insiders have sold a total of 233,951 shares of company stock valued at $16,654,206 in the last ninety days. 0.09% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY opened at $71.29 on Friday. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.44 and a quick ratio of 1.34. The stock’s fifty day moving average price is $72.13 and its two-hundred day moving average price is $74.01. Bristol-Myers Squibb has a one year low of $53.22 and a one year high of $80.59. The firm has a market cap of $152.22 billion, a price-to-earnings ratio of 23.68, a P/E/G ratio of 1.48 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last issued its quarterly earnings data on Wednesday, July 27th. The biopharmaceutical company reported $1.93 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.14. Bristol-Myers Squibb had a return on equity of 49.31% and a net margin of 14.04%. The firm had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.50 billion. During the same period in the prior year, the firm posted $1.93 EPS. The company’s revenue for the quarter was up 1.6% on a year-over-year basis. On average, equities analysts forecast that Bristol-Myers Squibb will post 7.5 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 7th will be issued a $0.54 dividend. This represents a $2.16 dividend on an annualized basis and a yield of 3.03%. The ex-dividend date is Thursday, October 6th. Bristol-Myers Squibb’s dividend payout ratio is 71.76%.

About Bristol-Myers Squibb

(Get Rating)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

Further Reading

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYGet Rating).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.